[go: up one dir, main page]

EE200200052A - HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid - Google Patents

HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid

Info

Publication number
EE200200052A
EE200200052A EEP200200052A EEP200200052A EE200200052A EE 200200052 A EE200200052 A EE 200200052A EE P200200052 A EEP200200052 A EE P200200052A EE P200200052 A EEP200200052 A EE P200200052A EE 200200052 A EE200200052 A EE 200200052A
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
compositions containing
reductase inhibitor
hmg reductase
hmg
Prior art date
Application number
EEP200200052A
Other languages
English (en)
Inventor
Richard Creekmore Joseph
Alfred Wiggins Norman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200200052(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200052A publication Critical patent/EE200200052A/et
Publication of EE04990B1 publication Critical patent/EE04990B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200052A 2000-01-26 2000-08-04 HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod EE04990B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions
PCT/GB2000/003014 WO2001054668A1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg reductase inhibitor

Publications (2)

Publication Number Publication Date
EE200200052A true EE200200052A (et) 2003-04-15
EE04990B1 EE04990B1 (et) 2008-04-15

Family

ID=9884259

Family Applications (3)

Application Number Title Priority Date Filing Date
EEP200200411A EE05221B1 (et) 2000-01-26 2000-08-04 HMG-CoA reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, mitmevalentse katiooniga anorgaanilise soola kasutamine ja stabiliseeritud farmatseutilise kompositsiooni valmistamismeetod
EEP200900047A EE05586B1 (et) 2000-01-26 2000-08-04 Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees
EEP200200052A EE04990B1 (et) 2000-01-26 2000-08-04 HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EEP200200411A EE05221B1 (et) 2000-01-26 2000-08-04 HMG-CoA reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, mitmevalentse katiooniga anorgaanilise soola kasutamine ja stabiliseeritud farmatseutilise kompositsiooni valmistamismeetod
EEP200900047A EE05586B1 (et) 2000-01-26 2000-08-04 Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees

Country Status (48)

Country Link
US (2) US6316460B1 (et)
EP (6) EP2266540A1 (et)
JP (3) JP4800467B2 (et)
KR (3) KR100698333B1 (et)
CN (3) CN101028268A (et)
AP (2) AP1879A (et)
AR (3) AR023624A1 (et)
AT (3) AT412063B (et)
AU (5) AU6580000A (et)
BE (2) BE1013413A3 (et)
BG (4) BG65234B1 (et)
BR (2) BR0003364A (et)
CA (3) CA2313783C (et)
CH (2) CH691347A5 (et)
CL (1) CL2007001807A1 (et)
CR (3) CR6568A (et)
CZ (3) CZ299105B6 (et)
DE (3) DE60001371T2 (et)
DK (3) DK1223918T3 (et)
EE (3) EE05221B1 (et)
ES (2) ES2171123B1 (et)
FI (3) FI111806B (et)
FR (2) FR2804025B1 (et)
GB (3) GB0001621D0 (et)
HK (6) HK1036935A1 (et)
HR (3) HRP20020097B1 (et)
HU (2) HU222578B1 (et)
IL (4) IL150513A0 (et)
IS (3) IS1940B (et)
IT (2) ITTO20000780A1 (et)
ME (4) MEP33708A (et)
MY (2) MY123650A (et)
NL (2) NL1015859C2 (et)
NO (4) NO312434B1 (et)
NZ (2) NZ519774A (et)
PL (2) PL196808B1 (et)
PT (3) PT102503B (et)
RS (1) RS50201B (et)
RU (2) RU2264210C2 (et)
SE (2) SE523471C2 (et)
SI (1) SI1223918T1 (et)
SK (2) SK11792000A3 (et)
TR (3) TR200200270T2 (et)
TW (2) TW553749B (et)
UA (2) UA51853C2 (et)
WO (2) WO2001054668A1 (et)
YU (1) YU52902A (et)
ZA (2) ZA200003997B (et)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
EP1274401B2 (en) † 2000-04-10 2014-08-13 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US20060039967A1 (en) * 2002-08-12 2006-02-23 Motohiro Ohta Amino acid-containing chewable
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
CA2657076A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
DK3395339T3 (da) * 2003-09-12 2019-07-22 Amgen Inc Hurtigt opløsende formulering af cinacalcet-hcl
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1601658A1 (en) * 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
JP4733047B2 (ja) * 2003-12-02 2011-07-27 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチンの特性評価のためのリファレンス・スタンダード
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
TW200539903A (en) * 2004-03-12 2005-12-16 Smithkline Beecham Plc Pharmaceutical formulations
NZ550942A (en) * 2004-05-04 2011-02-25 Innophos Inc Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
MX2007001558A (es) * 2004-08-06 2008-03-13 Transform Pharmaceuticals Inc Formulaciones novedosas de fenofibrato y metodos de tratamiento relacionados.
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
WO2006091770A2 (en) 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
CN101500555A (zh) * 2005-08-04 2009-08-05 变换药品公司 包含非诺贝特和他汀的新型制剂及相关治疗方法
MX2007004427A (es) * 2005-08-16 2007-06-14 Teva Pharma Intermedio de rosuvastatina cristalina.
DK1928409T3 (da) 2005-09-12 2012-11-05 Actelion Pharmaceuticals Ltd Stabil farmaceutisk sammensætning omfattende pyrimidin-sulfamid
ES2375643T3 (es) * 2005-10-31 2012-03-02 Kowa Company, Ltd. Preparación farmacéutica que presenta excelente fotoestabilidad.
CN101330919B (zh) * 2005-12-20 2012-12-05 力奇制药公司 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
WO2007125547A2 (en) * 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
HUE028475T2 (en) * 2006-10-09 2016-12-28 Msn Laboratories Private Ltd A novel process for the preparation of statins and their pharmaceutically acceptable salts
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
KR20090127904A (ko) * 2007-04-09 2009-12-14 싸이도우스 엘엘씨. 스타틴과 항비만제의 복합물
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
MX2010008466A (es) * 2008-01-30 2010-10-25 Lupin Ltd Formulaciones de liberación modificada de inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa.
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
US20100074947A1 (en) * 2008-06-13 2010-03-25 Adrian Brown Pharmaceutical Formulations
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
DK2306982T3 (en) * 2008-06-27 2015-04-20 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
ES2657416T3 (es) * 2008-06-27 2018-03-05 Krka, Torvarna Zdravil, D.D., Novo Mesto Composición farmacéutica que comprende una estatina
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
EP2464344A2 (en) 2009-08-13 2012-06-20 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
WO2012141160A1 (ja) * 2011-04-12 2012-10-18 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
AU2012260605B2 (en) 2011-05-20 2015-02-19 Astrazeneca Uk Limited Pharmaceutical composition of rosuvastatin calcium
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
US10952968B2 (en) * 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
US20160045497A1 (en) * 2013-03-12 2016-02-18 Lg Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
CN107072997A (zh) * 2014-11-11 2017-08-18 盐野义制药株式会社 含有对光不稳定的药物的多层片剂
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
CA3002916C (en) 2015-10-23 2024-06-11 Lyndra, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
US11992552B2 (en) 2015-12-08 2024-05-28 Lyndra Therapeutics, Inc. Geometric configurations for gastric residence systems
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
AU2017268840B2 (en) 2016-05-27 2022-02-10 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
CN110022861B (zh) 2016-09-30 2024-06-28 林德拉治疗公司 用于金刚烷类药物缓释的胃驻留系统
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
CN110996906A (zh) 2017-06-09 2020-04-10 林德拉有限公司 具有调节释放速度的膜的胃驻留系统
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
WO1990003973A1 (en) * 1988-10-06 1990-04-19 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
DK0475482T3 (da) 1990-09-13 1995-04-03 Akzo Nobel Nv Stabiliserede faste kemiske midler
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
ES2133158T3 (es) 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
PL186907B1 (pl) * 1995-12-22 2004-03-31 Kowa Co Kompozycja farmaceutyczna stabilizowana czynnikiem zasadowym
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
NZ508544A (en) 1998-06-05 2002-10-25 Warner Lambert Co Angiotensin converting enzyme inhibitors, such as quinapril, enalapril and indolapril, stabilised with 1-90 wt% magnesium oxide
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU3653301A (en) 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
GB0019029D0 (en) 2000-09-27
GB2358583B (en) 2002-02-06
SE0002826D0 (sv) 2000-08-04
FI121589B (fi) 2011-01-31
GB2358583A (en) 2001-08-01
EP1223918B1 (en) 2003-02-05
BE1013414A5 (fr) 2001-12-04
BE1013413A3 (fr) 2001-12-04
TR200201888T2 (tr) 2002-11-21
AU781269B2 (en) 2005-05-12
NZ531474A (en) 2007-04-27
SK11792000A3 (sk) 2001-12-03
ES2171123A1 (es) 2002-08-16
HU0003110D0 (en) 2000-10-28
IS2805B (is) 2012-09-15
CZ298411B6 (cs) 2007-09-26
AR060248A2 (es) 2008-06-04
JP3267960B2 (ja) 2002-03-25
NO20003968L (no) 2001-07-27
CA2315141C (en) 2009-08-18
SE0002827L (sv) 2001-07-27
ZA200003998B (en) 2000-08-14
CA2315141A1 (en) 2001-07-26
BG66159B1 (bg) 2011-09-30
AU2000264559A1 (en) 2001-08-07
PT102503A (pt) 2000-12-29
IL150513A0 (en) 2003-02-12
IS1940B (is) 2004-07-16
ES2155043B1 (es) 2001-12-01
HK1200368A1 (en) 2015-08-07
AT412062B (de) 2004-09-27
PL196808B1 (pl) 2008-02-29
HRP20020632A2 (en) 2004-12-31
EP2774609A1 (en) 2014-09-10
GB0001621D0 (en) 2000-03-15
GB2358582A (en) 2001-08-01
HRP20080525A2 (en) 2008-12-31
DE60001371D1 (de) 2003-03-13
AU738074B2 (en) 2001-09-06
KR100698333B1 (ko) 2007-03-23
AU5184100A (en) 2001-08-02
DK1223918T3 (da) 2003-04-28
EP1251831A1 (en) 2002-10-30
BR0003365A (pt) 2001-09-18
HUP0003110A3 (en) 2003-02-28
CZ299105B6 (cs) 2008-04-23
MEP33808A (hr) 2010-10-10
RU2206324C1 (ru) 2003-06-20
NO20071303L (no) 2001-07-27
AU2005202392C1 (en) 2016-06-02
EP2018853A1 (en) 2009-01-28
AU5184200A (en) 2001-08-02
NL1015859A1 (nl) 2001-07-27
DK200001171A (da) 2001-07-27
ITTO20000779A1 (it) 2002-02-04
PT1223918E (pt) 2003-06-30
NL1015858C2 (nl) 2001-07-27
CR10114A (es) 2008-08-21
ATE232088T1 (de) 2003-02-15
YU52902A (sh) 2006-01-16
KR20000072135A (ko) 2000-12-05
JP2001206877A (ja) 2001-07-31
DE10038108A1 (de) 2001-08-02
ATA13602000A (de) 2004-02-15
FI20001750L (fi) 2001-07-27
PL341853A1 (en) 2001-01-29
IL150513A (en) 2012-12-31
HK1047052A1 (zh) 2003-02-07
HK1040936A1 (en) 2002-06-28
AU2005202392A1 (en) 2005-06-30
RS50201B (sr) 2009-07-15
HU222578B1 (hu) 2003-08-28
CH691347A5 (de) 2001-07-13
RU2264210C2 (ru) 2005-11-20
MY122707A (en) 2006-04-29
NO327554B1 (no) 2009-08-10
HK1036934A1 (en) 2002-01-25
NO2010005I1 (no) 2010-05-03
CA2313783A1 (en) 2000-10-16
NO20003967D0 (no) 2000-08-04
HK1036935A1 (en) 2002-01-25
CN1319396A (zh) 2001-10-31
HRP20020097B1 (hr) 2010-12-31
DK178242B1 (da) 2015-09-28
AR025055A1 (es) 2002-11-06
GB2358582B (en) 2004-09-29
NZ519774A (en) 2004-04-30
PL341855A1 (en) 2001-07-30
NO20003967L (no) 2001-07-27
SE0002827D0 (sv) 2000-08-04
SI1223918T1 (en) 2003-06-30
EP2266540A1 (en) 2010-12-29
AP1449A (en) 2005-07-28
SE523481C2 (sv) 2004-04-20
FR2804025A1 (fr) 2001-07-27
CN100528161C (zh) 2009-08-19
ITTO20000779A0 (it) 2000-08-04
MEP33708A (hr) 2010-10-10
EP1223918A1 (en) 2002-07-24
IS8620A (is) 2007-03-07
BG66168B1 (bg) 2011-10-31
CN1149997C (zh) 2004-05-19
FR2795324A1 (fr) 2000-12-29
HK1040936B (zh) 2010-06-11
TWI228050B (en) 2005-02-21
RU2002122752A (ru) 2004-03-10
DE60001371T2 (de) 2004-01-22
AT412063B (de) 2004-09-27
JP4800988B2 (ja) 2011-10-26
SE523471C2 (sv) 2004-04-20
CZ290167B6 (cs) 2002-06-12
DE10038110B4 (de) 2006-06-29
HK1048950A1 (zh) 2003-04-25
BG106926A (bg) 2003-04-30
CR6687A (es) 2005-07-18
NO20003968D0 (no) 2000-08-04
CA2639407A1 (en) 2001-07-26
AU2005202392B2 (en) 2008-11-20
CR6568A (es) 2004-03-05
KR100388713B1 (ko) 2003-06-25
ITTO20000780A1 (it) 2000-11-04
ME00202B (me) 2010-10-10
CH700184B1 (de) 2010-07-15
CL2007001807A1 (es) 2008-01-18
TR200200270T2 (tr) 2002-06-21
CA2313783C (en) 2002-03-12
TW553749B (en) 2003-09-21
NO312434B1 (no) 2002-05-13
AP2002002409A0 (en) 2002-03-31
US6316460B1 (en) 2001-11-13
WO2001054668A1 (en) 2001-08-02
SK11782000A3 (sk) 2001-12-03
EE05586B1 (et) 2012-10-15
MY123650A (en) 2006-05-31
FI20001750A0 (fi) 2000-08-04
DK200001170A (da) 2001-01-27
HUP0003110A2 (hu) 2001-05-28
UA77156C2 (en) 2006-11-15
EE200200411A (et) 2003-12-15
SE0002826L (sv) 2001-07-27
AR023624A1 (es) 2002-09-04
WO2001054669A1 (en) 2001-08-02
FR2795324B1 (fr) 2002-05-17
AP2002002591A0 (en) 2002-09-30
IS6254A (is) 2002-01-29
CN1282581A (zh) 2001-02-07
EE200900047A (et) 2011-04-15
CZ20002883A3 (cs) 2000-10-11
YU5202A (sh) 2004-12-31
BR0003364A (pt) 2001-09-18
HRP20020632B1 (en) 2010-12-31
JP4800467B2 (ja) 2011-10-26
ME00191B (me) 2010-10-10
PT102504A (pt) 2001-07-31
FI20105657L (fi) 2010-06-10
AU781269C (en) 2006-11-30
CZ20002884A3 (cs) 2001-09-12
NO327675B1 (no) 2009-09-07
NL1015859C2 (nl) 2001-10-16
KR20010077840A (ko) 2001-08-20
FI20001749A0 (fi) 2000-08-04
HUP0003111A3 (en) 2003-03-28
DE10038110A1 (de) 2001-08-23
JP2001206847A (ja) 2001-07-31
ES2171123B1 (es) 2003-11-16
FI121365B (fi) 2010-10-29
IS6480A (is) 2002-07-23
JP2007182452A (ja) 2007-07-19
HU0003111D0 (en) 2000-10-28
IL147870A (en) 2003-10-31
IL147870A0 (en) 2002-08-14
EE05221B1 (et) 2009-10-15
FR2804025B1 (fr) 2002-08-23
IL187416A0 (en) 2008-02-09
US6548513B1 (en) 2003-04-15
ATA13612000A (de) 2004-02-15
GB0019028D0 (en) 2000-09-27
AP1879A (en) 2008-08-14
BG65234B1 (bg) 2007-09-28
BG106393A (en) 2002-07-31
HUP0003111A2 (hu) 2002-02-28
SK283872B6 (sk) 2004-03-02
FI20001749L (fi) 2001-07-27
KR20030036492A (ko) 2003-05-09
ES2155043A1 (es) 2001-04-16
HRP20020097A2 (en) 2002-06-30
ZA200003997B (en) 2000-08-14
FI111806B (fi) 2003-09-30
TR200701171T2 (tr) 2007-04-24
AU6580000A (en) 2001-08-07
CN101028268A (zh) 2007-09-05
PT102503B (pt) 2004-02-27
EE04990B1 (et) 2008-04-15
EP2133070A1 (en) 2009-12-16
BG110353A (en) 2009-09-30
CA2639407C (en) 2011-09-13
UA51853C2 (uk) 2002-12-16

Similar Documents

Publication Publication Date Title
EE200200052A (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid
DK1373259T3 (da) Pyridazinonaldosereduktaseinhibitorer
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
ITMI20010748A0 (it) Composizioni farmaceutiche
FI20011478L (fi) Farmaseuttinen koostumus
ATE293970T1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
EE05020B1 (et) Glburiidi ravimkoostis
PT1458377E (pt) Composicoes farmaceuticas contendo tegaserod
EE200300589A (et) Ravimkoostised
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
FI20022128A0 (fi) Farmaseuttinen koostumus
NO20031095L (no) Farmasoytiske sammensetninger
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
EE200200689A (et) Ravimkoostised
HK1077230A1 (en) Medicinal composition hmg-coa reductase inhibitor
FI5468U1 (fi) Farmaseuttinen koostumus
AU2002254116A1 (en) Compounds and pharmaceutical compositions for inhibiting mrp1

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231